img

Global Molecular Cancer Therapeutics Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Molecular Cancer Therapeutics Market Research Report 2024

Molecular cancer therapeutics focuses on basic research that has implications for cancer therapeutics in the following areasExperimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology.
According to MRAResearch’s new survey, global Molecular Cancer Therapeutics market is projected to reach US$ 261.5 million in 2033, increasing from US$ 139 million in 2022, with the CAGR of 10.2% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Molecular Cancer Therapeutics market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Molecular Cancer Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics
Segment by Type
Monoclonal Antibodies
Small Molecule Inhibitors

Segment by Application


Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Molecular Cancer Therapeutics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Cancer Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Monoclonal Antibodies
1.2.3 Small Molecule Inhibitors
1.3 Market by Application
1.3.1 Global Molecular Cancer Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Leukemia
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Molecular Cancer Therapeutics Market Perspective (2018-2033)
2.2 Molecular Cancer Therapeutics Growth Trends by Region
2.2.1 Global Molecular Cancer Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Molecular Cancer Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Molecular Cancer Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Molecular Cancer Therapeutics Market Dynamics
2.3.1 Molecular Cancer Therapeutics Industry Trends
2.3.2 Molecular Cancer Therapeutics Market Drivers
2.3.3 Molecular Cancer Therapeutics Market Challenges
2.3.4 Molecular Cancer Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Cancer Therapeutics Players by Revenue
3.1.1 Global Top Molecular Cancer Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Molecular Cancer Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Molecular Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Cancer Therapeutics Revenue
3.4 Global Molecular Cancer Therapeutics Market Concentration Ratio
3.4.1 Global Molecular Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Cancer Therapeutics Revenue in 2022
3.5 Molecular Cancer Therapeutics Key Players Head office and Area Served
3.6 Key Players Molecular Cancer Therapeutics Product Solution and Service
3.7 Date of Enter into Molecular Cancer Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Cancer Therapeutics Breakdown Data by Type
4.1 Global Molecular Cancer Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Molecular Cancer Therapeutics Forecasted Market Size by Type (2024-2033)
5 Molecular Cancer Therapeutics Breakdown Data by Application
5.1 Global Molecular Cancer Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Molecular Cancer Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Molecular Cancer Therapeutics Market Size (2018-2033)
6.2 North America Molecular Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Molecular Cancer Therapeutics Market Size by Country (2018-2023)
6.4 North America Molecular Cancer Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Molecular Cancer Therapeutics Market Size (2018-2033)
7.2 Europe Molecular Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Molecular Cancer Therapeutics Market Size by Country (2018-2023)
7.4 Europe Molecular Cancer Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Cancer Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Molecular Cancer Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Molecular Cancer Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Molecular Cancer Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Molecular Cancer Therapeutics Market Size (2018-2033)
9.2 Latin America Molecular Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Molecular Cancer Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Molecular Cancer Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Cancer Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Molecular Cancer Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Molecular Cancer Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Molecular Cancer Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Phoenix Molecular Designs
11.1.1 Phoenix Molecular Designs Company Detail
11.1.2 Phoenix Molecular Designs Business Overview
11.1.3 Phoenix Molecular Designs Molecular Cancer Therapeutics Introduction
11.1.4 Phoenix Molecular Designs Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.1.5 Phoenix Molecular Designs Recent Development
11.2 Prelude Therapeutics
11.2.1 Prelude Therapeutics Company Detail
11.2.2 Prelude Therapeutics Business Overview
11.2.3 Prelude Therapeutics Molecular Cancer Therapeutics Introduction
11.2.4 Prelude Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.2.5 Prelude Therapeutics Recent Development
11.3 Tempus
11.3.1 Tempus Company Detail
11.3.2 Tempus Business Overview
11.3.3 Tempus Molecular Cancer Therapeutics Introduction
11.3.4 Tempus Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.3.5 Tempus Recent Development
11.4 Bracco
11.4.1 Bracco Company Detail
11.4.2 Bracco Business Overview
11.4.3 Bracco Molecular Cancer Therapeutics Introduction
11.4.4 Bracco Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.4.5 Bracco Recent Development
11.5 iOmx Therapeutics
11.5.1 iOmx Therapeutics Company Detail
11.5.2 iOmx Therapeutics Business Overview
11.5.3 iOmx Therapeutics Molecular Cancer Therapeutics Introduction
11.5.4 iOmx Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.5.5 iOmx Therapeutics Recent Development
11.6 OncoDNA
11.6.1 OncoDNA Company Detail
11.6.2 OncoDNA Business Overview
11.6.3 OncoDNA Molecular Cancer Therapeutics Introduction
11.6.4 OncoDNA Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.6.5 OncoDNA Recent Development
11.7 Sapience Therapeutics
11.7.1 Sapience Therapeutics Company Detail
11.7.2 Sapience Therapeutics Business Overview
11.7.3 Sapience Therapeutics Molecular Cancer Therapeutics Introduction
11.7.4 Sapience Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.7.5 Sapience Therapeutics Recent Development
11.8 Caris Life Sciences
11.8.1 Caris Life Sciences Company Detail
11.8.2 Caris Life Sciences Business Overview
11.8.3 Caris Life Sciences Molecular Cancer Therapeutics Introduction
11.8.4 Caris Life Sciences Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.8.5 Caris Life Sciences Recent Development
11.9 Hera Biolabs
11.9.1 Hera Biolabs Company Detail
11.9.2 Hera Biolabs Business Overview
11.9.3 Hera Biolabs Molecular Cancer Therapeutics Introduction
11.9.4 Hera Biolabs Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.9.5 Hera Biolabs Recent Development
11.10 CV6 Therapeutics
11.10.1 CV6 Therapeutics Company Detail
11.10.2 CV6 Therapeutics Business Overview
11.10.3 CV6 Therapeutics Molecular Cancer Therapeutics Introduction
11.10.4 CV6 Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.10.5 CV6 Therapeutics Recent Development
11.11 Carrick Therapeutics
11.11.1 Carrick Therapeutics Company Detail
11.11.2 Carrick Therapeutics Business Overview
11.11.3 Carrick Therapeutics Molecular Cancer Therapeutics Introduction
11.11.4 Carrick Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.11.5 Carrick Therapeutics Recent Development
11.12 Foundation Medicine
11.12.1 Foundation Medicine Company Detail
11.12.2 Foundation Medicine Business Overview
11.12.3 Foundation Medicine Molecular Cancer Therapeutics Introduction
11.12.4 Foundation Medicine Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.12.5 Foundation Medicine Recent Development
11.13 Cybrexa Therapeutics
11.13.1 Cybrexa Therapeutics Company Detail
11.13.2 Cybrexa Therapeutics Business Overview
11.13.3 Cybrexa Therapeutics Molecular Cancer Therapeutics Introduction
11.13.4 Cybrexa Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023)
11.13.5 Cybrexa Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Molecular Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Small Molecule Inhibitors
Table 4. Global Molecular Cancer Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Molecular Cancer Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Molecular Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Molecular Cancer Therapeutics Market Share by Region (2018-2023)
Table 8. Global Molecular Cancer Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Molecular Cancer Therapeutics Market Share by Region (2024-2033)
Table 10. Molecular Cancer Therapeutics Market Trends
Table 11. Molecular Cancer Therapeutics Market Drivers
Table 12. Molecular Cancer Therapeutics Market Challenges
Table 13. Molecular Cancer Therapeutics Market Restraints
Table 14. Global Molecular Cancer Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Molecular Cancer Therapeutics Market Share by Players (2018-2023)
Table 16. Global Top Molecular Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Cancer Therapeutics as of 2022)
Table 17. Ranking of Global Top Molecular Cancer Therapeutics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Molecular Cancer Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Molecular Cancer Therapeutics Product Solution and Service
Table 21. Date of Enter into Molecular Cancer Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Molecular Cancer Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Molecular Cancer Therapeutics Revenue Market Share by Type (2018-2023)
Table 25. Global Molecular Cancer Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Molecular Cancer Therapeutics Revenue Market Share by Type (2024-2033)
Table 27. Global Molecular Cancer Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Molecular Cancer Therapeutics Revenue Market Share by Application (2018-2023)
Table 29. Global Molecular Cancer Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Molecular Cancer Therapeutics Revenue Market Share by Application (2024-2033)
Table 31. North America Molecular Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Molecular Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Molecular Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Molecular Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Molecular Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Molecular Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Molecular Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Molecular Cancer Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Molecular Cancer Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Molecular Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Molecular Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Molecular Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Molecular Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Molecular Cancer Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Molecular Cancer Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 46. Phoenix Molecular Designs Company Detail
Table 47. Phoenix Molecular Designs Business Overview
Table 48. Phoenix Molecular Designs Molecular Cancer Therapeutics Product
Table 49. Phoenix Molecular Designs Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 50. Phoenix Molecular Designs Recent Development
Table 51. Prelude Therapeutics Company Detail
Table 52. Prelude Therapeutics Business Overview
Table 53. Prelude Therapeutics Molecular Cancer Therapeutics Product
Table 54. Prelude Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 55. Prelude Therapeutics Recent Development
Table 56. Tempus Company Detail
Table 57. Tempus Business Overview
Table 58. Tempus Molecular Cancer Therapeutics Product
Table 59. Tempus Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 60. Tempus Recent Development
Table 61. Bracco Company Detail
Table 62. Bracco Business Overview
Table 63. Bracco Molecular Cancer Therapeutics Product
Table 64. Bracco Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 65. Bracco Recent Development
Table 66. iOmx Therapeutics Company Detail
Table 67. iOmx Therapeutics Business Overview
Table 68. iOmx Therapeutics Molecular Cancer Therapeutics Product
Table 69. iOmx Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 70. iOmx Therapeutics Recent Development
Table 71. OncoDNA Company Detail
Table 72. OncoDNA Business Overview
Table 73. OncoDNA Molecular Cancer Therapeutics Product
Table 74. OncoDNA Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 75. OncoDNA Recent Development
Table 76. Sapience Therapeutics Company Detail
Table 77. Sapience Therapeutics Business Overview
Table 78. Sapience Therapeutics Molecular Cancer Therapeutics Product
Table 79. Sapience Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Sapience Therapeutics Recent Development
Table 81. Caris Life Sciences Company Detail
Table 82. Caris Life Sciences Business Overview
Table 83. Caris Life Sciences Molecular Cancer Therapeutics Product
Table 84. Caris Life Sciences Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Caris Life Sciences Recent Development
Table 86. Hera Biolabs Company Detail
Table 87. Hera Biolabs Business Overview
Table 88. Hera Biolabs Molecular Cancer Therapeutics Product
Table 89. Hera Biolabs Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Hera Biolabs Recent Development
Table 91. CV6 Therapeutics Company Detail
Table 92. CV6 Therapeutics Business Overview
Table 93. CV6 Therapeutics Molecular Cancer Therapeutics Product
Table 94. CV6 Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 95. CV6 Therapeutics Recent Development
Table 96. Carrick Therapeutics Company Detail
Table 97. Carrick Therapeutics Business Overview
Table 98. Carrick Therapeutics Molecular Cancer Therapeutics Product
Table 99. Carrick Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 100. Carrick Therapeutics Recent Development
Table 101. Foundation Medicine Company Detail
Table 102. Foundation Medicine Business Overview
Table 103. Foundation Medicine Molecular Cancer Therapeutics Product
Table 104. Foundation Medicine Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 105. Foundation Medicine Recent Development
Table 106. Cybrexa Therapeutics Company Detail
Table 107. Cybrexa Therapeutics Business Overview
Table 108. Cybrexa Therapeutics Molecular Cancer Therapeutics Product
Table 109. Cybrexa Therapeutics Revenue in Molecular Cancer Therapeutics Business (2018-2023) & (US$ Million)
Table 110. Cybrexa Therapeutics Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Molecular Cancer Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Molecular Cancer Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Monoclonal Antibodies Features
Figure 4. Small Molecule Inhibitors Features
Figure 5. Global Molecular Cancer Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Molecular Cancer Therapeutics Market Share by Application: 2022 VS 2033
Figure 7. Lung Cancer Case Studies
Figure 8. Breast Cancer Case Studies
Figure 9. Colorectal Cancer Case Studies
Figure 10. Leukemia Case Studies
Figure 11. Others Case Studies
Figure 12. Molecular Cancer Therapeutics Report Years Considered
Figure 13. Global Molecular Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 14. Global Molecular Cancer Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 15. Global Molecular Cancer Therapeutics Market Share by Region: 2022 VS 2033
Figure 16. Global Molecular Cancer Therapeutics Market Share by Players in 2022
Figure 17. Global Top Molecular Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Cancer Therapeutics as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Molecular Cancer Therapeutics Revenue in 2022
Figure 19. North America Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 20. North America Molecular Cancer Therapeutics Market Share by Country (2018-2033)
Figure 21. United States Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Canada Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Molecular Cancer Therapeutics Market Share by Country (2018-2033)
Figure 25. Germany Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. France Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. U.K. Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Italy Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Russia Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Nordic Countries Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Molecular Cancer Therapeutics Market Share by Region (2018-2033)
Figure 33. China Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. Japan Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. South Korea Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. Southeast Asia Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. India Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Australia Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Molecular Cancer Therapeutics Market Share by Country (2018-2033)
Figure 41. Mexico Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Brazil Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Molecular Cancer Therapeutics Market Share by Country (2018-2033)
Figure 45. Turkey Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Saudi Arabia Molecular Cancer Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Phoenix Molecular Designs Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 48. Prelude Therapeutics Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 49. Tempus Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 50. Bracco Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 51. iOmx Therapeutics Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 52. OncoDNA Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 53. Sapience Therapeutics Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 54. Caris Life Sciences Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 55. Hera Biolabs Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 56. CV6 Therapeutics Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 57. Carrick Therapeutics Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 58. Foundation Medicine Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 59. Cybrexa Therapeutics Revenue Growth Rate in Molecular Cancer Therapeutics Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries